Key Points:
• Anagrelide is an FDA approved drug for blood disorders
• Strong scientific rationale for its use in cancer
• SUDA has global IP rights across multiple delivery systems
• EU patent office notice to grant anagrelide patent
• Plans to advance into Phase 1 cancer clinical trials underway
For more information, download the attached PDF.
Download this document
